Completed PHASE2 NCT00003276

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer

A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors

Sponsor: Alliance for Clinical Trials in Oncology

Updated 6 times since 2017 Last updated: Jul 1, 2016 Started: Mar 31, 1998 Primary completion: Mar 31, 2001 Completion: Mar 31, 2001

This PHASE2 trial investigates Gallbladder Cancer and is currently completed. Alliance for Clinical Trials in Oncology leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Bismarck, United States , Cedar Rapids, United States , Danville, United States , Des Moines, United States , Fargo, United States , Grand Forks, United States , New Orleans, United States , Omaha, United States , Peoria, United States and 11 more locations